Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01399398 · ClinicalTrials.gov registry record · Phase 1
Imaging of CB1 Receptors Using (11C)SD5024
A Phase 1 study, sponsored by National Institute of Mental Health (NIMH).
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT01399398: Clinical Trial Phase 1 study, sponsored by National Institute of Mental Health (NIMH).
NCT01399398 is a Phase 1 study that was terminated before completion, run by National Institute of Mental Health (NIMH). The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01399398, a Phase 1 study, was terminated before completion, sponsored by National Institute of Mental Health (NIMH).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Background: \- The cannabinoid type 1 (CB1) receptor is a protein found on some brain cells. It may play a role in obesity or some psychiatric disorders such as schizophrenia. Imaging studies like positron emission tomography (PET) can show where CB1 receptors are located. A new radioactive chemical, 11C-SD5024, may be able to show these receptors more clearly than previous radioactive chemicals. Better images of CB1 receptors in the brain may help improve our understanding of obesity and psychiatric disorders. This information may lead to better treatments. Objectives: \- To test how well a new radioactive chemical, 11C-SD5024, is taken up by the brain during imaging studies. Eligibility: \- Healthy volunteers between 18 and 50 years of age who are able to have positron emission tomography scans. Design: * All participants will be screened with a physical exam, medical history, and blood tests. * Participants will be in one of three groups for the study. Each group will receive 11C-SD5024 and have a different set of imaging studies. * Group 1 will have a magnetic resonance imaging (MRI) scan and PET scan of the brain. They will also have blood and urine tests. * Group 2 will have a whole-body PET scan, as well as blood and urine tests. * Group 3 will have an MRI scan of the brain, followed by two PET scans of the brain. They will also have blood and urine tests. The two PET scans can happen on the same day or on two different days.
Interventions
- PROCEDURE Blood Sampling
- PROCEDURE Brain Scan-PET
- PROCEDURE Brain Scan-MRI
- PROCEDURE Arterial Line
- PROCEDURE Venous Line
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2011-06-22 |
| Est. Completion | 2013-12-18 |
| Phase | Phase 1 |
Why NCT01399398 stopped before completion
NCT01399398 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 5 interventions - of which Blood Sampling is the first listed.
NCT01399398 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01399398 about?
NCT01399398 is a clinical study titled "Imaging of CB1 Receptors Using (11C)SD5024". Background: \- The cannabinoid type 1 (CB1) receptor is a protein found on some brain cells. It may play a role in obesity or some psychiatric disorders such as schizophrenia. Imaging studies like positron emission tomography (PET) can show where CB1 receptors are located. A new radioactive chemica...
What is the current status of trial NCT01399398?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2011-06-22. Estimated completion is 2013-12-18.
What interventions are being tested in trial NCT01399398?
The interventions under investigation include: Blood Sampling (PROCEDURE), Brain Scan-PET (PROCEDURE), Brain Scan-MRI (PROCEDURE), Arterial Line (PROCEDURE), Venous Line (PROCEDURE).
Who is sponsoring clinical trial NCT01399398?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01399398's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI